TITLE

PROPRANOLOL EFFECTIVE IN SHRINKING INFANTILE HEMANGIOMA

PUB. DATE
September 2011
SOURCE
Contemporary Pediatrics;Sep2011, Vol. 28 Issue 9, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports a study from Australia which demonstrated that the beta-blocker popranolol is effective in shrinking infantile hemangiomas (IHs) in young children. It mentions that the study examined focal hemangiomas in 40 children up to 5 years of age. The study revealed that early treatment of IHs can decrease scarring and disfigurement if propranolol is used as a first line option.
ACCESSION #
66481139

 

Related Articles

  • Guanfacine monotherapy for ADHD/ASD comorbid with Tourette syndrome: a case report. Okazaki, Kosuke; Yamamuro, Kazuhiko; Iida, Junzo; Kishimoto, Toshifumi // Annals of General Psychiatry;3/11/2019, Vol. 18 Issue 1, pN.PAG 

    Background: Patients with attention deficit/hyperactivity disorder (ADHD) often experience comorbid conditions, such as autism spectrum disorder (ASD) and Tourette syndrome (TS). Although pharmacotherapies are effective for treating ADHD, they are likely to elicit a variety of adverse effects....

  • Erratum to: ARB-Based Single-Pill Platform to Guide a Practical Therapeutic Approach to Hypertensive Patients. Volpe, Massimo; Sierra, Alejandro; Kreutz, Reinhold; Laurent, St├ęphane; Manolis, Athanasios // High Blood Pressure & Cardiovascular Prevention;Jun2014, Vol. 21 Issue 2, p149 

    A correction to the article "ARB-Based Single-Pill Platform to Guide a Practical Therapeutic Approach to Hypertensive Patients" that was published online on March 29, 2014 is presented.

  • GENERIC DRUG TRENDS. First Generic ARB Approval Draws a Wave of Comparative Studies. Buffery, Dalia // American Health & Drug Benefits;Jan2011, Vol. 4 Issue 1, p48 

    The article reports on an increase which has been seen in the U.S. in the use of comparative effectiveness research studies which are used to determine best pharmaceutical therapies and reduce their costs. A discussion of a decision which the U.S. Food and Drug Administration made on April 9,...

  • Renal denervation: potential indications and review of trial data. Raphael, Claire E // Clinical Medicine;2014 Supplement, Vol. 14, ps38 

    Renal sympathetic denervation is a novel, endovascular treatment with potential utility in resistant hypertension. First pioneered in humans in 2010, conflicting data exist regarding the efficacy of this treatment. This article will review the evidence to date, the scientific rationale for...

  • INTUNIV EXTENDED-RELEASE TABLETS COADMINISTERED WITH STIMULANTS SHOWED ADHD SYMPTOM IMPROVEMENT.  // Psychiatry (1550-5952);Oct2010, Vol. 7 Issue 10, p9 

    The article presents the findings of the study from Shire PLC which revealed the effectiveness of Intuniv extended-release tablets for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents.

  • Combination Therapy in Hypertension: What Are the Best Options According to Clinical Pharmacology Principles and Controlled Clinical Trial Evidence? Taddei, Stefano // American Journal of Cardiovascular Drugs;Jun2015, Vol. 15 Issue 3, p185 

    Despite extensive debate about the first choice for treating essential hypertension, monotherapy effectively normalizes blood pressure (BP) values in only a limited number of hypertensive patients. Thus, the aim of combination therapy should always be to both improve BP control and to reduce...

  • Selexipag: A Review in Pulmonary Arterial Hypertension. Duggan, Sean; Keam, Susan; Burness, Celeste // American Journal of Cardiovascular Drugs;Feb2017, Vol. 17 Issue 1, p73 

    Selexipag (Uptravi) is an orally active, first-in-class, selective prostacyclin IP receptor agonist. Selexipag was approved recently in the EU for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II or III as combination therapy in...

  • Combination Drug Therapy for Hypertension. AHC MEDIA // Internal Medicine Alert;3/15/2019, Vol. 41 Issue 5, p0 

    A large regional database study from Italy revealed that initial combination therapy for newly diagnosed hypertension results in fewer major adverse cardiovascular events at one year compared to monotherapy.

  • Antihypertensives.  // Reactions Weekly;10/13/2012, Issue 1423, p9 

    The article describes two cases of male neonates who developed renal failure and oligohydramnios after being exposed in utero to antihypertensives.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics